---
document_datetime: 2025-08-28 13:18:42
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rivaroxaban-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: rivaroxaban-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.274179
conversion_datetime: 2025-12-28 13:25:35.54769
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rivaroxaban Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA_IN / | This was an application for a group of | 27/08/2025                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000292730                   | variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted   |            |            | PL   |                                                                                                                                                                                                                                                                                  |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 5 year / EMA/R/0000249659 | - Renewal - Accepted                                                                                                                                                                                                                                                                                                                                         | 19/06/2025 | 06/08/2025 |      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Rivaroxaban Accord in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |